Last reviewed · How we verify
AZD5153
AZD5153 is a selective BET bromodomain inhibitor that disrupts the interaction between bromodomains and acetylated histones, leading to changes in gene expression.
AZD5153 is a selective BET bromodomain inhibitor that disrupts the interaction between bromodomains and acetylated histones, leading to changes in gene expression. Used for Relapsed or refractory hematologic malignancies.
At a glance
| Generic name | AZD5153 |
|---|---|
| Also known as | BRD4 inhibitor |
| Sponsor | Acerta Pharma BV |
| Drug class | BET bromodomain inhibitor |
| Target | BET bromodomain |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
BET bromodomain inhibitors like AZD5153 block the binding of BET proteins to acetylated histones, which modulates the transcription of genes involved in cell proliferation and survival, particularly in cancer cells.
Approved indications
- Relapsed or refractory hematologic malignancies
Common side effects
- Thrombocytopenia
- Neutropenia
- Anemia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD5153 CI brief — competitive landscape report
- AZD5153 updates RSS · CI watch RSS
- Acerta Pharma BV portfolio CI